Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results
Impax Asset Management's "Impax US Sustainable Economy Fund" released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
Merck & Co. Inc. (MRK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 24,873,327 | $2,618,166,478 | +4% | 0.89% |
| 2. | Harris Associates Natixis Global Asset Management | 14,088,705 | $1,482,977,135 | +44% | 1.87% |
| 3. | AQR Capital Management Cliff Asness | 11,249,363 | $1,184,107,948 | +6% | 0.62% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 9,944,123 | $1,046,718,387 | -47% | 0.61% |
| 5. | Citadel Investment Group Ken Griffin | 6,821,331 | $718,013,301 | +605% | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $88.25 | 2,833 | $249,999.98 | 2,933 | 2025-02-06 | Filing | |
| $88.50 | 15,000 | $1,327,500.00 | 16,000 | 2025-02-05 | Filing | |
| $113.68 | 3 | $341.04 | 20,599 | 2023-04-26 | Filing | |
| $105.47 | 136 | $14,343.92 | 20,631 | 2023-03-20 | Filing | |
| $109.20 | 11 | $1,201.20 | 20,495 | 2023-02-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $121.46 | 10,000 | $1,214,562.00 | 60,615 | 2026-02-12 | Filing | |
| $117.52 | 10,235 | $1,202,843.81 | 92,035 | 2026-02-10 | Filing | |
| $118.41 | 10,000 | $1,184,101.00 | 70,615 | 2026-02-09 | Filing | |
| $119.15 | 38,835 | $4,627,275.69 | 68,916 | 2026-02-09 | Filing | |
| $119.15 | 56,792 | $6,766,891.74 | 68,916 | 2026-02-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 254,322,763 | $26,770,014,033 | 0.39% | |
| 2. | 219,095,465 | $23,061,988,586 | 0.39% | |
| 3. | 120,040,168 | $12,737,503,943 | 0.43% | |
| 4. | 86,435,458 | $9,098,196,310 | 1.59% | |
| 5. | 60,047,984 | $6,307,571,859 | 0.39% |
News See All
Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA® and KEYTRUDA QLEX™ Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+
Merck & Co., Inc. (NYSE:MRK) is one of the best medical research stocks to buy according to hedge funds. Merck & Co., Inc.
10 Best Medical Research Stocks to Buy According to Hedge Funds
On January 27, Sarah James, Cantor Fitzgerald analyst, appeared on CNBC’s ‘Squawk on the Street’ to talk about the healthcare insurance sector and the stocks coming under pressure.
Merck & Co., Inc. (MRK): A Bull Case Theory
We came across a bullish thesis on Merck & Co., Inc. on R. Dennis’s Substack’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on MRK.
Scotiabank Lifts Merck (MRK) Target as Execution Continues to Impress
On February 4, Scotiabank raised its price target on Merck & Co., Inc. (NYSE:MRK) to $136 from $120 and maintained an Outperform rating.
15 Best Wide Moat Dividend Stocks to Invest in
Wide-moat stocks are companies with durable advantages that help them keep competitors at bay. According to an S&P Global report, a large market share can be a sign of a strong economic moat.
Jim Cramer Looked At These 7 Stocks Recently
The clients win, the purveyors lose. Hardware companies triumph, software companies shrivel up and die.
Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript
Peter Dannenbaum: Welcome to the Merck & Co., Inc., Rahway, New Jersey, USA Fourth Quarter Sales and Earnings Conference Call.
Where is Merck & Co. (MRK) Headed According to Wall Street?
Merck & Co., Inc. (NYSE:MRK) is one of the best long term low volatility stocks to invest in. Merck & Co., Inc.
15 Stocks on Jim Cramer’s Recent Game Plan
Sick of earnings yet? Sorry, got another big week ahead, roughly 20% of the S&P 500. Living hell if you follow a lot of companies like I do. Fortunately, we're coming in cold.
Hedge Fund Resource Center Billionaire Hedge Funds
